Magnesium is one of 171 small molecule programs targeting Ischemic stroke. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
119 competitors in Ischemic Stroke
Magnesium
Reminyl
Intravenous Thrombolysis
Butylphthalide
Tegoprazan
Rhtnk-Tpa
Zastaprazan
SGLT-2 Inhibitors
SP-8203
Tenecteplase or Alteplase
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details